Urovant Sciences Ltd (NASDAQ:UROV) Q1 2019 Earnings Conference Call - Final Transcript

Aug 13, 2019 • 04:30 pm ET

Previous

Urovant Sciences Ltd (NASDAQ:UROV) Q1 2019 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Q & A
Analyst
Biren Amin

And then, I guess, just on the additional indications for vibegron. Can you talk about the IBS pain indication, where that trial is currently in terms of enrollment? So I just wanted to ask on that indication. Thanks.

Executive
Keith A. Katkin

Yeah, absolutely. So the study continues to enroll. And as we've said, expect to have top line data in 2020 as we get closer to the end of the year and closer to end of enrollment and it could be able to refine that timeline. But we still have a little ways to go with that study, but certainly expect that it's going to be a data read out in 2020 and we're going to push to make it as early in 2020 as we can.

Analyst
Biren Amin

Okay. And then I guess just on a 902 Phase 2a trial protocol. Are you dosing patients with a 24,000 microgram dose? And then, I think, you previously mentioned that you would dose on a single administration to assess for durability. I just want to get your thoughts on how long you'll follow these patients in the 2a trial and whether these patients coming into this study will have failed on Botox and/or neuromodulation?

Executive
Cornelia Haag-Molkenteller

Okay, to answer your first question after consulting with the experts, they advised against taking Botox. So listen to the Phase 3 study, because there is no reason to know why there is Botox failures. So definitely we will have patients who are -- who are non-Botox failures for the bladder. And then the first, as you -- as you noticed the 24,000 microgram was the highest dose in the Phase 1b and that was effective for them to start with this. And then we're going to have a data monitoring safety board review well in a dose, one higher dose and we're going to follow in total for 48 weeks.

Analyst
Biren Amin

Great. Thank you.

Executive
Keith A. Katkin

Thank you.

Operator
Operator

Thank you. At this time, I'd like to turn the call back over to Keith Katkin for any closing remarks. Sir?

Executive
Keith A. Katkin

Thank you very much. I appreciate everybody's time this afternoon and look forward to keeping everyone uprise of our progress through the remainder of the year. Have a great afternoon and great evening.

Operator
Operator

[Operator Closing Remarks]